Compare BridgeBio Pharma Inc (BBIO) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Western Digital Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Western Digital Corp trades at $444.82 (market cap $151.09B). The key difference: Western Digital Corp is far larger — about 9.1× BridgeBio Pharma Inc's market cap, and Western Digital Corp pays a 0.14% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WDC | |
|---|---|---|
Market Cap | $16.61B | $151.09B |
Sector | Health | Technology |
52-Week High | $90.17 | $746.23 |
52-Week Low | $47.29 | $74.66 |
Enterprise Value | $18.16B | $150.56B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
WDC trades at $434.3, down 3.81% over 24 hours, with a bearish technical signal as it hovers near the pivot point of $440. The company has shown strong earnings beats in recent quarters, with Q2 2026 EPS of $3.56 surpassing the $3.31 estimate, and maintains robust profitability margins, including a net income margin of 72.95% for 2025. Revenue for 2025 was $9.52B, with a significant turnaround to net income of $1.86B from prior losses, indicating operational recovery amid high cloud demand.
The outlook is mixed, with analyst consensus strongly bullish (72.13% buy ratings) and a price target of $665.15 suggesting substantial upside, but risks include high valuation multiples like a P/E of 17.89 and EV/EBITDA of 29.99, competitive pressures in HDD storage, and recent post-earnings sell-offs due to margin concerns. Investors should weigh the growth potential from AI-driven storage demand against cyclical and valuation headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
